Videos

How Nu.Q® Discover can support drug developers

April 04, 2024

Share
Tweet
Share on Facebook
Share

Watch highlights from a recent Biomarkers and Companion Diagnostic Conference 2024, where our Volition team showcased our Nu.Q^{^®} Discover assays to drug developers.

Poster & Publications
Physical isolation of tumour associated ctDNA fragments for novel AML liquid biopsy
Poster & Publications
Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients

Share
Tweet
Share on Facebook
Share

Subscribe for Volition product updates.

Or, click here for Investor Updates and press releases.

"*" indicates required fields

Receive product updates for:

Animal Health

Human Health

Name

First Name Last Name

Company Name*

Your Email Address*

CAPTCHA

How Nu.Q® Discover can support drug developers

Related Articles

Physical isolation of tumour associated ctDNA fragments for novel AML liquid biopsy

Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients

Subscribe for Volition product updates.

Or, click here for Investor Updates and press releases.

Contact